The use of cabazitaxel over abiraterone acetate or enzalutamide may continue as a standard of care in men with metastatic castration-resistant prostate cancer who were previously treated with docetaxel and either of those 2 androgen receptor-targeted agents.
The combination of cabozantinib and atezolizumab showed clinically meaningful activity in patients with metastatic castration-resistant prostate cancer.
Darolutamide (Nubeqa) plus androgen deprivation therapy led to a 31% reduction in the risk of death compared with placebo and ADT in patients with nonmetastatic castration-resistant prostate cancer.​​
The phase 3 IMvigor010 trial comparing adjuvant atezolizumab with observation in patients with muscle-invasive urothelial carcinoma failed to meet its primary endpoint of disease-free survival.
Patients with advanced renal cell carcinoma who were treated with cabozantinib (Cabometyx) following both immunotherapy and non-IO regimens demonstrated promising responses.
Pyrotinib plus capecitabine achieved a better progression-free survival than lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and chemotherapy.
In the phase 2 trial EMPOWER-CSCC-1, up to 3 years of follow-up showed continued response rates, and a clinically meaningful survival and duration of response for cemiplimab-rwlc in patients with advanced cutaneous squamous cell carcinoma.
Baseline and posttreatment circulating tumor DNA positivity was associated with worse radiologic progression-free survival in patients with metastatic castration-resistant prostate cancer.
The combination of pembrolizumab and axitinib continued to demonstrate a clinically significant improvement in progression-free and overall survival compared with sunitinib in patients with previously untreated, advanced renal cell carcinoma.
Brian A. Van Tine, MD, PhD, discusses next steps with ADP-A2M4 SPEAR T cells in advanced solid tumors.
Combining the anti–PD-1 agent tislelizumab with chemotherapy improved progression-free survival compared with chemotherapy alone as a frontline treatment in Chinese patients with advanced squamous non–small cell lung cancer.
The addition of durvalumab to standard chemotherapy continued to demonstrate an improvement in overall survival for patients with treatment-naïve extensive-stage small cell lung cancer.
The combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) demonstrated promising objective responses in patients with urothelial carcinoma who progressed after receiving platinum-containing chemotherapy.
Axicabtagene ciloleucel (axi-cel; Yescarta) demonstrated significant and durable clinical benefit as well as a manageable safety profile in patients with relapsed or refractory indolent non-Hodgkin lymphoma.
Fam-trastuzumab deruxtecan-nxki (Enhertu) demonstrated promising clinical activity in patients with HER2-positive metastatic colorectal cancer, as well as in those with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.
Teclistamab (JNJ-64007957) appeared to be a safe and efficacious treatment for patients with relapsed/refractory multiple myeloma.
Results from the phase III SPARTAN trial showed that apalutamide plus androgen deprivation therapy significantly improved overall survival when compared with ADT plus placebo in patients with nonmetastatic castration-resistant prostate cancer.
The pharmacodynamic profile of KTE-X19, an autologous anti-CD19 CAR T-cell therapy, was associated with efficacy and treatment-related neurological events among patients with relapsed/refractory mantle cell lymphoma treated within the ZUMA-2 trial.
The combination of encorafenib and binimetinib demonstrated continuing benefit in overall survival and progression-free survival for patients with BRAF V600–mutant melanoma.
An ongoing study of CC-92480 in combination with dexamethasone demonstrated favorable activity and safety data in patients with heavily pretreated relapsed or refractory multiple myeloma.
The latest results from the phase 3 BEACON CRC study continued to show an overall survival benefit for encorafenib plus cetuximab with or without binimetinib compared with cetuximab plus irinotecan-containing regimens in patients with BRAF V600E–mutated metastatic colorectal cancer.
Imaging with 18F-DCFPyL-PET/CT outperformed that of standard imaging modalities—such as bone scan, CT, MRI, and FDG PET—in patients with biochemically relapsed prostate cancer.
Findings showed that AMG 330 was safe and tolerable in treating patients with relapsed or refractory acute myeloid leukemia, with cytokine release syndrome as the most frequent and expected adverse event.
Findings from a 5-year analysis of the phase 3 COMBI-AD trial validated the long-term benefit of adjuvant dabrafenib and trametinib in patients with resected, stage III BRAF V600E/K-mutant melanoma.
Treatment with pembrolizumab improved progression-free survival after subsequent therapy for patients with PD-L1–positive, relapsed/refractory head and neck squamous cell carcinoma.
AMG 510, a novel KRAS G12C inhibitor, demonstrated early evidence of a consistent safety profile and anticancer activity across a range of advanced KRAS G12C-mutant solid tumors other than non–small cell lung cancer and colorectal cancer.
Clinical outcomes in patients with recurrent ovarian cancer who were treated with niraparib plus bevacizumab were significantly improved when compared with niraparib alone.
Relugolix (Relumina) demonstrated superiority over leuprolide (Lupron) in sustained testosterone (T)-suppression through 48 weeks in patients with advanced prostate cancer.
Treatment with pembrolizumab induced a 4.9-month progression-free survival benefit over brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma.
Mirvetuximab soravtansine in combination with bevacizumab to treat patients with platinum-agnostic ovarian cancer demonstrated encouraging overall response rates regardless of platinum status with a favorable tolerability profile.
